Having trouble accessing articles? Reset your cache.

Priority Review roundup: Roche-PTC, Intercept, Zogenix

FDA granted Priority Review to a trio of compounds Monday, accepting NDAs from partners Roche and PTC, as well as Intercept and Zogenix to treat neurological and hepatic diseases.

Risdiplam from Roche (SIX:ROG; OTCQX:RHHBY) and PTC Therapeutics Inc. (NASDAQ:PTCT) was granted Priority Review to treat spinal muscular atrophy (SMA). Its PDUFA date is May 24.

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE